Modified J-CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy.
advanced prostate cancer
overall survival
progression-free survival
risk stratification
treatment response
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
04
09
2020
revised:
29
09
2020
accepted:
02
10
2020
pubmed:
25
10
2020
medline:
5
8
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
The J-CAPRA score is an assessment tool which stratifies risk and predicts outcome of primary androgen deprivation therapy (ADT) using prostate-specific antigen, Gleason score, and clinical TNM staging. Here, we aimed to assess the generalisability of this tool in multi-ethnic Asians. Performance of J-CAPRA was evaluated in 782 Malaysian and 16,946 Japanese patients undergoing ADT from the Malaysian Study Group of Prostate Cancer (M-CaP) and Japan Study Group of Prostate Cancer (J-CaP) databases, respectively. Using the original J-CAPRA, 69.6% metastatic (M1) cases without T and/or N staging were stratified as intermediate-risk disease in the M-CaP database. To address this, we first omitted clinical T and N stage variables, and calculated the score on a 0-8 scale in the modified J-CAPRA scoring system for M1 patients. Notably, treatment decisions of M1 cases were not directly affected by both T and N staging. The J-CAPRA score threshold was adjusted for intermediate (modified J-CAPRA score 3-5) and high-risk (modified J-CAPRA score ≥6) groups in M1 patients. Using J-CaP database, validation analysis showed that overall survival, prostate cancer-specific survival, and progression-free survival of modified intermediate and high-risk groups were comparable to those of original J-CAPRA (p > 0.05) with Cohen's coefficient of 0.65. Around 88% M1 cases from M-CaP database were reclassified into high-risk category. Modified J-CAPRA scoring system is instrumental in risk assessment and treatment outcome prediction for M1 patients without T and/or N staging.
Identifiants
pubmed: 33098372
doi: 10.1002/cam4.3548
pmc: PMC7774710
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9346-9352Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Urol. 2005 Jun;173(6):1938-42
pubmed: 15879786
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Cancer. 2008 Dec 1;113(11):3075-99
pubmed: 18823041
Eur Urol. 2018 Jun;73(6):847-855
pubmed: 29475737
Jpn J Clin Oncol. 2007 Oct;37(10):775-81
pubmed: 17965423
BJU Int. 2016 Jan;117(1):102-9
pubmed: 25238114
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Clin Oncol. 2009 Sep 10;27(26):4306-13
pubmed: 19667269
Jpn J Clin Oncol. 2004 Jun;34(6):329-36
pubmed: 15333685
Cancer Med. 2020 Dec;9(24):9346-9352
pubmed: 33098372
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Lancet. 2011 Dec 17;378(9809):2104-11
pubmed: 22056152
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Urology. 1996 Nov;48(5):773-7
pubmed: 8911524
BMJ Open. 2019 Jun 22;9(6):e029149
pubmed: 31230029
BJU Int. 2019 Sep;124(3):373-382
pubmed: 31077523
J Clin Oncol. 2015 Jul 1;33(19):2143-50
pubmed: 25691677
Eur Urol. 2017 May;71(5):705-709
pubmed: 27616723